Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-12
2006-12-12
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266400, C544S284000, C544S293000
Reexamination Certificate
active
07148230
ABSTRACT:
The invention concerns quinazoline derivatives of Formula Iwherein R1and R2have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB, particularly EGF, receptor tyrosine kinases.
REFERENCES:
patent: 3985749 (1976-10-01), Foster
patent: 5252586 (1993-10-01), Cain et al.
patent: 5457105 (1995-10-01), Barker
patent: 5616582 (1997-04-01), Barker
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5770599 (1998-06-01), Gibson
patent: 5770603 (1998-06-01), Gibson
patent: 5821246 (1998-10-01), Brown et al.
patent: 5866572 (1999-02-01), Barker et al.
patent: 6004967 (1999-12-01), McMahon et al.
patent: 6126917 (2000-10-01), Mishani et al.
patent: 6177433 (2001-01-01), Uckun et al.
patent: 6225318 (2001-05-01), Sobolov-Jaynes et al.
patent: 6653305 (2003-11-01), Himmelsbach et al.
patent: 6740651 (2004-05-01), Himmelsbach et al.
patent: 6924285 (2005-08-01), Himmelsbach et al.
patent: 2002/0049197 (2002-04-01), Himmelsbach et al.
patent: 2002/0082271 (2002-06-01), Himmelsbach et al.
patent: 2002/0169180 (2002-11-01), Himmelsbach et al.
patent: 2002/0173509 (2002-11-01), Himmelsbach et al.
patent: 2002/0177601 (2002-11-01), Himmelsbach et al.
patent: 2003/0149062 (2003-08-01), Jung et al.
patent: 2003/0158196 (2003-08-01), Jung et al.
patent: 2004/0044014 (2004-03-01), Himmelsbach et al.
patent: 2004/0048880 (2004-03-01), Himmelsbach et al.
patent: 2005/0215574 (2005-09-01), Bradbury et al.
patent: 0520722 (1992-12-01), None
patent: 0566226 (1993-10-01), None
patent: 0602851 (1994-06-01), None
patent: 0 607 439 (1994-07-01), None
patent: 0635507 (1995-01-01), None
patent: 1283039 (2003-02-01), None
patent: 2033894 (1980-05-01), None
patent: 2160201 (1985-12-01), None
patent: WO 92/14746 (1992-09-01), None
patent: 92/20642 (1992-11-01), None
patent: 94/27965 (1994-12-01), None
patent: WO 95/00146 (1995-01-01), None
patent: WO 95/03283 (1995-02-01), None
patent: 95/15758 (1995-06-01), None
patent: 95/24190 (1995-09-01), None
patent: 96/15118 (1996-05-01), None
patent: 96/33981 (1996-09-01), None
patent: 96/30347 (1996-10-01), None
patent: 96/33977 (1996-10-01), None
patent: 96/33978 (1996-10-01), None
patent: 96/33979 (1996-10-01), None
patent: 96/33980 (1996-10-01), None
patent: 97/03069 (1997-01-01), None
patent: 97/18813 (1997-05-01), None
patent: 97/22596 (1997-06-01), None
patent: 97/30034 (1997-08-01), None
patent: 97/30035 (1997-08-01), None
patent: 97/32856 (1997-09-01), None
patent: 97/38994 (1997-10-01), None
patent: 97/42187 (1997-11-01), None
patent: 98/13354 (1998-04-01), None
patent: 98/389884 (1998-09-01), None
patent: 99/10349 (1999-03-01), None
patent: 00/10981 (2000-03-01), None
patent: 00/12497 (2000-03-01), None
patent: 00/20402 (2000-04-01), None
patent: 00/51991 (2000-08-01), None
patent: 00/51587 (2000-09-01), None
patent: 00/55141 (2000-09-01), None
patent: 00/55162 (2000-09-01), None
patent: 00/56338 (2000-09-01), None
patent: 00/56720 (2000-09-01), None
patent: 00/68203 (2000-11-01), None
patent: 00/78735 (2000-12-01), None
patent: 01/04102 (2001-01-01), None
patent: 01/21594 (2001-03-01), None
patent: 01/21595 (2001-03-01), None
patent: 01/21596 (2001-03-01), None
patent: 01/32651 (2001-05-01), None
patent: 01/66099 (2001-09-01), None
patent: 01/66099 (2001-09-01), None
patent: 01/76586 (2001-10-01), None
patent: 01/77085 (2001-10-01), None
patent: 01/94341 (2001-12-01), None
patent: 02/16352 (2002-02-01), None
patent: 02/18351 (2002-03-01), None
patent: 02/18370 (2002-03-01), None
patent: 02/18372 (2002-03-01), None
patent: 02/18373 (2002-03-01), None
patent: 02/18376 (2002-03-01), None
patent: 02/34711 (2002-05-01), None
patent: 02/41882 (2002-05-01), None
patent: 02/41882 (2002-05-01), None
patent: 02/50043 (2002-06-01), None
patent: 02/092577 (2002-11-01), None
patent: 02/092578 (2002-11-01), None
patent: WO 02/092579 (2002-11-01), None
patent: 03/000188 (2003-01-01), None
patent: 03/000188 (2003-01-01), None
patent: 03/040108 (2003-05-01), None
patent: 03/040109 (2003-05-01), None
patent: 03/040109 (2003-05-01), None
patent: 03/045364 (2003-06-01), None
patent: 03/045364 (2003-06-01), None
patent: 03/045395 (2003-06-01), None
patent: 03/082290 (2003-10-01), None
patent: 03/082831 (2003-10-01), None
patent: WO 2005/028469 (2005-03-01), None
patent: WO 2005/028470 (2005-03-01), None
patent: WO 2005/030757 (2005-04-01), None
March J., Advanced Organic Chemistry—Reactions, Mechanisms, and Structure, 4thEd., © 1992, John Wiley & Sons, New York, NY, p. 357.
Bridges et al., J. Med. Chem., 1996, 39(1), 267-276.
Chevalier et al., J. Cell Science, 1999, 112(24), 4785-4791.
Gazit et al., Bioorg. Med. Chem., 1996, 4(8), 1203-1207.
Ghosh et al., Anti-Cancer Drug Des., 1999, 14(5), 403-410.
Hennequin et al., J. Med. Chem., 1999, 42(26), 5369-5389.
Hennequin et al., J. Med. Chem., 2002, 45, 1300-1312.
Myers et al., Bioorg. Med. Chem. Lett., 1997, 7(4), 417-420.
Rewcastle, J. Med. Chem., 1995, 38, 3482-3487.
Singh et al., J. Enzyme Inhibition, 1998, 13(2) 125-134.
Small et al., J. Med. Chem., 2000, 43(16), 3199.
Wright et al., Biorg. Med. Chem. Lett., 2001, 11(1), 17-21.
“Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer” by Mendelsohn et al., Journal of Clinical Oncology, vol. 21, No. 14 (Jul. 2003), pp. 2787-2799.
“Targeting the Epidermal Growth Factor Receptor for Cancer Therapy” by Mendelsohn, Journal of Clinical Oncology, vol. 20, No. 18s (Sep. 15 Supplement) 2002, pp. 2s-13s.
“Epidermal Growth Factor Receptor Mutations, Small-Molecule Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions” by Pao et al., Journal of Clinical Oncology, vol. 23, No. 11, Apr. 10, 2005.
Bradbury Robert Hugh
Hennequin Laurent Francois Andre
Kettle Jason Grant
McCabe James
Turner Andrew
AstraZeneca AB
Finnegan Henderson Farabow Garrett & Dunner, LLP.
Truong Tamthom N.
Wilson James O.
LandOfFree
Quinazoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3720487